DK1773314T3 - Anvendelse af l-carnitin til behandling af kardiovaskulære sygdomme - Google Patents

Anvendelse af l-carnitin til behandling af kardiovaskulære sygdomme

Info

Publication number
DK1773314T3
DK1773314T3 DK05755616.9T DK05755616T DK1773314T3 DK 1773314 T3 DK1773314 T3 DK 1773314T3 DK 05755616 T DK05755616 T DK 05755616T DK 1773314 T3 DK1773314 T3 DK 1773314T3
Authority
DK
Denmark
Prior art keywords
carnitine
infarction
grams
care
days
Prior art date
Application number
DK05755616.9T
Other languages
Danish (da)
English (en)
Inventor
Aleardo Koverech
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of DK1773314T3 publication Critical patent/DK1773314T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05755616.9T 2004-07-13 2005-06-21 Anvendelse af l-carnitin til behandling af kardiovaskulære sygdomme DK1773314T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000346A ITRM20040346A1 (it) 2004-07-13 2004-07-13 Uso della l-carnitina per il trattamento di patologie cardiovascolari.
PCT/EP2005/006657 WO2006005415A2 (en) 2004-07-13 2005-06-21 Use of l-carnitine and glucose for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
DK1773314T3 true DK1773314T3 (da) 2012-05-07

Family

ID=34971575

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05755616.9T DK1773314T3 (da) 2004-07-13 2005-06-21 Anvendelse af l-carnitin til behandling af kardiovaskulære sygdomme

Country Status (22)

Country Link
US (2) US7879908B2 (zh)
EP (1) EP1773314B1 (zh)
JP (1) JP5230195B2 (zh)
KR (1) KR101296479B1 (zh)
CN (2) CN101087602B (zh)
AT (1) ATE542529T1 (zh)
AU (1) AU2005262050B2 (zh)
BR (1) BRPI0513303A8 (zh)
CA (1) CA2569888C (zh)
CY (1) CY1112686T1 (zh)
DK (1) DK1773314T3 (zh)
ES (1) ES2380913T3 (zh)
HK (2) HK1113542A1 (zh)
HR (1) HRP20120178T1 (zh)
IT (1) ITRM20040346A1 (zh)
ME (1) ME01345B (zh)
MX (1) MXPA06014665A (zh)
PL (1) PL1773314T3 (zh)
PT (1) PT1773314E (zh)
RS (1) RS52253B (zh)
SI (1) SI1773314T1 (zh)
WO (1) WO2006005415A2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086543A1 (es) * 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
JPS6415220A (en) 1987-07-06 1989-01-19 Mitsubishi Electric Corp Tension control device for utilizing maximum torque and maximum electric current of winding motor
JPH06102624B2 (ja) * 1990-08-10 1994-12-14 アース製薬株式会社 非心臓由来の不整脈防止薬
IT1261695B (it) * 1993-06-02 1996-05-29 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e alcanoil l-carnitine nella conservazione del sangue per trasfusioni e soluzioni stabilizzatrici che le contengono.
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
AU1295700A (en) * 1998-11-26 2000-06-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia
DE69932860T2 (de) * 1999-10-11 2007-08-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von l-carnitin und seinen alkanoyl-derivaten als osmotisches mittel in lösungen für medizinische verwendung
EP1499580B1 (en) * 2002-04-01 2012-03-28 The Governors of the University of Alberta Compounds that stimulate glucose utilization and methods of use
ITRM20030178A1 (it) * 2003-04-17 2004-10-18 Sigma Tau Ind Farmaceuti Uso della l-carnitina per il trattamento di patologie cardiovascolari.

Also Published As

Publication number Publication date
US20070207970A1 (en) 2007-09-06
CN101087602A (zh) 2007-12-12
CN102349923B (zh) 2016-04-27
US20110086917A1 (en) 2011-04-14
CA2569888C (en) 2013-08-13
HRP20120178T1 (hr) 2012-05-31
ATE542529T1 (de) 2012-02-15
PT1773314E (pt) 2012-03-29
HK1166003A1 (zh) 2012-10-19
AU2005262050B2 (en) 2011-02-24
PL1773314T3 (pl) 2012-06-29
EP1773314B1 (en) 2012-01-25
WO2006005415A3 (en) 2006-05-26
SI1773314T1 (sl) 2012-04-30
MXPA06014665A (es) 2007-03-12
CN102349923A (zh) 2012-02-15
JP5230195B2 (ja) 2013-07-10
ME01345B (me) 2012-10-31
CY1112686T1 (el) 2016-02-10
CN101087602B (zh) 2011-09-14
ITRM20040346A1 (it) 2004-10-13
US7879908B2 (en) 2011-02-01
JP2008517872A (ja) 2008-05-29
WO2006005415A2 (en) 2006-01-19
HK1113542A1 (en) 2008-10-10
US8394854B2 (en) 2013-03-12
EP1773314A2 (en) 2007-04-18
ES2380913T3 (es) 2012-05-21
BRPI0513303A8 (pt) 2017-12-26
BRPI0513303A (pt) 2008-05-06
KR101296479B1 (ko) 2013-08-13
KR20070039541A (ko) 2007-04-12
CA2569888A1 (en) 2006-01-19
AU2005262050A1 (en) 2006-01-19
RS52253B (en) 2012-10-31

Similar Documents

Publication Publication Date Title
ES2577930T3 (es) Derivados de triazina para retrasar el inicio de la diabetes tipo 1
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
AR040682A1 (es) Forma de dosificacion una vez al dia de pramipexol
EA200971073A1 (ru) Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
PL404315A1 (pl) Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
CA2593171A1 (en) Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart diseases
AR036312A1 (es) Composicion farmaceutica
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
ECSP077843A (es) Tratamiento o prevención del prurito
JP7208139B2 (ja) 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
DK1773314T3 (da) Anvendelse af l-carnitin til behandling af kardiovaskulære sygdomme
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
MA28036A1 (fr) Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil
PT1408977E (pt) Terapia de combinacao para o tratamento de falha cardiaca
RU2012107483A (ru) Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек
MXPA05007612A (es) Uso de l-carnitina para el tratamiento de enfermedades cardiovasculares.
JP2006045200A (ja) 間質性膀胱炎の治療薬
ROY et al. Milestones In Diabetes Research
Prabhu et al. Digital gangrene due to dopamine infusion-a case report
Ayache et al. Methylphenidate in a patient with depression and respiratory insufficiency
McDaniel Antidepressant activity of linezolid
JP2008517872A5 (zh)
Placebo-Controlled Original Research Efficacy and Safety of Adjunctive Armodafinil
Hotel First-ever international conference on prevention of dementia